Cefpirome as empirical treatment for febrile neutropenia in patients with hematologic malignancies

Haematologica

Volumn 90, Issue 7, 2005, Pages 1005-1006

  Timmers, Gert Jan ^a   Van Vuurden, Dannis G ^a   Swart, Eleonora L ^a   Simoons Smit, Alberdina M ^a   Huijgens, Peter C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cefpirome; Cephalosporins; Fever; Neutropenia; Pharmacokinetics

Indexed keywords

AMPHOTERICIN B; AZITHROMYCIN; CEFPIROME; CIPROFLOXACIN; FLUCONAZOLE;

ADULT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PATHOGENESIS; RASH; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; FEMALE; FEVER; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA;

EID: 22544446201     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Bauduer F, Cousin T, Boulat O, Rigal-Huguet F, Molina L, Fegueux N, et al. A randomized prospective multicentre trial of cefpirome versus piperacillin-tazobactam in febrile neutropenia. Leuk Lymphoma 2001;42:379-86.
2. Norrby SR, Geddes AM, Shah PM. Randomized comparative trial of cefpirome versus ceftazidime in the empirical treatment of suspected bacteraemia or sepsis. Multicentre Study Group. J Antimicrob Chemother 1998;42:503-9.
3. Hoogkamp-Korstanje JA, Verduyn LF, Meis JF. Cefpirome: epidemiological survey in intensive care units and hematological units in The Netherlands. The Dutch Study Group. Diagn Microbiol Infect Dis 1998;31:489-91.
4. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51.
5. Wiseman LR, Lamb HM. Cefpirome. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;54:117-40.
6. Fernandes C, Pritchard R, Morris A, Benn R. In vitro evaluation of cefpirome: an Australasian study of isolates from intensive care unit and hematology/oncology patients. The Cefpirome Study Group. Diagn Microbiol Infect Dis 1998;31:493-5.
7. Lipman J, Wallis SC, Rickard CM, Fraenkel D. Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Intensive Care Med 2001;27:363-70.